scholarly journals PO-429 Identification of the right immunostimulatory chemotherapeutic partner for anti-CD70 immunotherapy in non-small cell lung cancer

2018 ◽  
Author(s):  
T Flieswasser ◽  
J Van Loenhout ◽  
K Zwaenepoel ◽  
C Rolfo ◽  
F Lardon ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
The Right

A Man Presenting with Sudden Weakness and Pain of the Right Hand, by Non-Small Cell Lung Cancer with Brain Metastases

Clinical Pain ◽  
2019 ◽  
Vol 18 (2) ◽  
pp. 88-91
Author(s):  
Won Jin Sung ◽  
Bo Young Hong ◽  
Joon Sung Kim ◽  
Jae Wan Yoo ◽  
Seong Hoon Lim
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Right Hand ◽  
The Right

scholarly journals Reactivation of TB during administration of durvalumab after chemoradiotherapy for non-small-cell lung cancer: a case report

Immunotherapy ◽  
2020 ◽  
Author(s):  
Yasuhiro Kato ◽  
Yasutaka Watanabe ◽  
Yuki Yamane ◽  
Hideaki Mizutani ◽  
Futoshi Kurimoto ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Checkpoint Inhibitors ◽  
Chest Ct ◽  
Small Cell ◽  
Small Cell Lung ◽  
Intermittent Fever ◽  
Unresectable Stage ◽  
The Right

Background: Tuberculosis (TB) is considered to be an adverse effect of treatment with immune checkpoint inhibitors. Methodology & results: Our case was a 75-year-old woman diagnosed with unresectable stage III non-small-cell lung cancer. After radical chemoradiotherapy was completed, durvalumab was initiated as a consolidation therapy. However, since chest CT showed appearances of infiltration shadows scattered in the periphery of the lungs after five doses of immunotherapy, duruvalumab was discontinued. 6 weeks later, the patient was aware of intermittent fever. Chest CT scan showed the appearance of a tree-in-bud pattern in the right lung. Acid-fast bacilli stain of sputum was positive and the PCR test was positive for Mycobacterium tuberculosis. Conclusion: Duruvalumab as PD-L1 blockade may activate TB.

scholarly journals Metastatic Ureteral Involvement of Non-Small Cell Lung Cancer

2011 ◽  
Vol 2011 ◽  
pp. 1-3 ◽  
Author(s):  
Koichi Kodama ◽  
Tetsuya Imao ◽  
Kazuto Komatsu
Keyword(s):  
Computed Tomography ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Malignant Tumors ◽  
Lower Lobe ◽  
Small Cell ◽  
Small Cell Lung ◽  
Primary Tumors ◽  
The Right

Metastases from a variety of malignant tumors can involve the ureters, but ureteral involvement by lung cancer is extremely rare and usually described at autopsy. We report a rare case of a 76-year-old man who presented with a three-month history of right flank dullness and was noted to have a nonhomogeneous retroperitoneal mass with hydronephrosis of the right kidney on computed tomography of the abdomen. Computed tomography of the thorax showed a nodule in the lower lobe, measuring3×2 cm, in the right lung. After excluding the presence of other primary tumors and metastases, we reached a final diagnosis of solitary retroperitoneal metastasis of adenocarcinoma of the lung. Although rare, in patients of non-small cell lung cancer, presence of hydronephrosis should alert the physician to the possibility of metastasis.

scholarly journals Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report

Medicina ◽  
2021 ◽  
Vol 57 (6) ◽  
pp. 547
Author(s):  
Nobutaka Kataoka ◽  
Yusuke Kunimatsu ◽  
Rei Tsutsumi ◽  
Nozomi Tani ◽  
Izumi Sato ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Metabolic Response ◽  
Previous Treatment ◽  
Standard Of Care ◽  
Small Cell ◽  
Small Cell Lung ◽  
Vascular Bed ◽  
The Right

Chemoimmunotherapy has become the standard of care as the first-line treatment of advanced or recurrent non-small-cell lung cancer (NSCLC). The bevacizumab-containing chemoimmunotherapy regimen is theoretically more effective than a non-bevacizumab-containing regimen via two mechanisms: a superior outcome of bevacizumab-containing chemothrerapy than the standard platinum doublet regimen, and the synergistic effect of bevacizumab with an immune checkpoint inhibitor (ICI). Bevacizumab effectively normalizes vascularization, especially when the vascular bed is damaged by previous treatment. Bevacizumab promotes immunomodulation when used with ICI. We describe a patient with nonsquamous NSCLC who returned 2.5 years after definitive chemoradiotherapy for postoperative locoregional recurrence in the right supraclavicular lymph node. Considering the destroyed vascular bed due to prior chemoradiotherapy, attaining vascular normalization was critical for effective drug delivery. The patient was treated with a bevacizumab-containing chemoimmunotherapy regimen, which resulted in a complete metabolic response. The patient responded well for 23 months and is receiving ongoing treatment. Thus, bevacizumab-containing chemoimmunotherapy could be advantageous in some recurrent cases after chemoradiotherapy.

Sign in / Sign up

Export Citation Format

Share Document